{
    "organizations": [],
    "uuid": "ead572f8e539ec6202472394e35e002021558e17",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-adverum-biotechnologies-extends-co/brief-adverum-biotechnologies-extends-collaboration-agreement-with-editas-medicine-idUSFWN1PK1KW",
    "ord_in_thread": 0,
    "title": "BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - Adverum Biotechnologies Inc:\n* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC\n* ADVERUM BIOTECHNOLOGIES - UNDER TERMS OF EXTENDED AGREEMENT, ADVERUM AND EDITAS ARE EXTENDING RESEARCH PERIOD THROUGH Q3 OF 2018\n* SAYS EDITAS MAINTAINS A SERIES OF OPTIONS EXERCISABLE BETWEEN NOW AND AUGUST 2020 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-26T05:35:00.000+02:00",
    "crawled": "2018-01-26T21:42:12.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "adverum",
        "biotechnology",
        "inc",
        "announces",
        "extension",
        "collaboration",
        "agreement",
        "editas",
        "medicine",
        "inc",
        "adverum",
        "biotechnology",
        "term",
        "extended",
        "agreement",
        "adverum",
        "editas",
        "extending",
        "research",
        "period",
        "q3",
        "say",
        "editas",
        "maintains",
        "series",
        "option",
        "exercisable",
        "august",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}